, a bio/informatics shared resource is still "open for business" - Visit the CDS website

Endovascular thrombolysis for pediatric cerebral sinus venous thrombosis with tissue plasminogen activator and abciximab.

Khan IS, Ladner TR, Satti KF, Ehtesham M, Jordan LC, Singer RJ
J Neurosurg Pediatr. 2014 13 (1): 68-71

PMID: 24180679 · DOI:10.3171/2013.9.PEDS13335

Cerebral sinus venous thrombosis (CSVT) is a relatively rare but potentially devastating disease. Medical management of CSVT with systemic anticoagulation has been the mainstay treatment strategy with these patients. However, some patients may not respond to this treatment or may present with very severe symptoms indicating more aggressive management strategies. The authors present the case of a pediatric patient who presented with severe CSVT, who underwent successful recanalization with endovascular tissue plasminogen activator (tPA) and abciximab. To the authors' knowledge there are no cases of endovascular thrombolysis for CSVT described in the literature in which abciximab has been used in conjunction with tPA. The authors also review the literature regarding the agents used and outcome in pediatric patients with CSVT after endovascular thrombolysis. The use of abciximab in conjunction with tPA may be considered in patients whose blood is hypercoagulable and in whom the treatment strategy is to obtain acute recanalization and long-term venous patency. However, the use of adjunctive agents increases the risk of hemorrhagic complications and must be done judiciously.

MeSH Terms (16)

Abciximab Adolescent Antibodies, Monoclonal Anticoagulants Cerebral Infarction Endovascular Procedures Headache Humans Immunoglobulin Fab Fragments Magnetic Resonance Imaging Male Parietal Lobe Sinus Thrombosis, Intracranial Thrombolytic Therapy Tissue Plasminogen Activator Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities: